Daily Respiratory Research Analysis
Three impactful studies reshape respiratory care: an RCT shows mobile health pulmonary rehabilitation is equivalent to center-based programs for COPD, a multinational cohort finds extremely high mortality in cancer patients with ARDS without benefit from ECMO, and a nationwide registry/meta-analysis shows anticoagulation does not improve survival in pulmonary arterial hypertension. Together, they inform scalable care models, ICU decision-making, and de-implementation of low-yield therapies.
Summary
Three impactful studies reshape respiratory care: an RCT shows mobile health pulmonary rehabilitation is equivalent to center-based programs for COPD, a multinational cohort finds extremely high mortality in cancer patients with ARDS without benefit from ECMO, and a nationwide registry/meta-analysis shows anticoagulation does not improve survival in pulmonary arterial hypertension. Together, they inform scalable care models, ICU decision-making, and de-implementation of low-yield therapies.
Research Themes
- Digital and remote pulmonary rehabilitation for COPD
- Outcomes and technology use (ECMO) in ARDS among oncology patients
- Therapeutic value of anticoagulation in pulmonary arterial hypertension
Selected Articles
1. Mobile health pulmonary rehabilitation (m-PR): a randomised controlled equivalence trial.
This multicentre single-blind equivalence RCT (n=90) showed that 8 weeks of mobile health pulmonary rehabilitation achieved equivalent gains in 6-minute walk distance versus center-based PR and yielded superior improvements in health status (CAT). Findings support mHealth PR as an effective, scalable alternative for COPD rehabilitation.
Impact: Demonstrates with randomized evidence that a digital model can replace resource-intensive center-based pulmonary rehabilitation while maintaining clinical effectiveness and improving patient-reported health status.
Clinical Implications: Health systems can deploy mHealth PR to expand access, reduce waitlists, and deliver equivalent functional gains with improved health status in COPD. Programs should ensure digital literacy support and tele-coaching for optimal adherence.
Key Findings
- m-PR achieved equivalent improvement in 6MWD compared with center-based PR within a 30 m equivalence margin.
- m-PR produced superior improvement in CAT health status compared with center-based PR.
- Trial used intention-to-treat analysis over 8 weeks with single-blind, multicentre design.
Methodological Strengths
- Randomised, single-blind, multicentre equivalence design with intention-to-treat analysis
- Prespecified equivalence margins for both functional and patient-reported outcomes
Limitations
- Sample size modest (n=90) and short intervention duration (8 weeks)
- Generalizability may depend on digital literacy and access to technology
Future Directions: Evaluate long-term maintenance, cost-effectiveness, and implementation strategies across diverse health systems, including hybrid PR models and support for digitally underserved populations.
BACKGROUND: Mobile health (mHealth) is a novel model of care that may overcome barriers to pulmonary rehabilitation (PR) access. This study determined if mHealth PR was equivalent to centre-based PR (CB-PR) in improving exercise capacity and health status in people with chronic obstructive pulmonary disease (COPD). METHOD: Single-blinded, multicentre, randomised controlled equivalence trial using an intention-to-treat analysis. Participants completed 8 weeks of either mHealth PR, using the mobile PR (m-PR) application and supported by telephone calls, or CB-PR. Co-primary outcomes, measured at baseline and end-intervention, were change in 6 minute walk distance (6MWD) and COPD assessment test (CAT) score, with an equivalence margin of 30 m and 2 points, respectively. RESULTS: 90 participants were randomised (mean (SD), m-PR n = 44: age 75 (7) years; forced expiratory volume in one second (FEV
2. Acute respiratory distress syndrome in patients with cancer: the YELENNA prospective multinational observational cohort study.
In 715 cancer patients with ARDS across 13 countries, 90-day mortality was 73.2% overall and 82.2% in severe ARDS, with no survival benefit from venovenous ECMO after double-adjusted analyses. Predictors of mortality included older age, peripheral vascular disease, severe ARDS, acute kidney injury, and time-limited ICU trials, whereas lymphoma was associated with lower mortality.
Impact: Provides the largest prospective multinational characterization of ARDS in cancer, highlighting extraordinary mortality and the lack of ECMO benefit in severe cases, which directly informs ICU goals-of-care and resource allocation.
Clinical Implications: For oncology patients with ARDS—especially severe forms—clinicians should prioritize early, nuanced goals-of-care discussions and carefully individualize ECMO decisions, as routine ECMO use is unlikely to improve survival. Risk factors can aid prognostication and triage.
Key Findings
- Overall 90-day mortality was 73.2%; severe ARDS subgroup had 82.2% mortality.
- No survival benefit of venovenous ECMO in severe ARDS after overlap- and propensity-weighted Cox modeling (aHR 1.12; 95% CI 0.65–1.94).
- Independent mortality predictors: older age, peripheral vascular disease, severe ARDS at inclusion, acute kidney injury, and time-limited ICU trial; lymphoma associated with lower mortality.
Methodological Strengths
- Prospective, multinational cohort across 13 countries with large sample size (n=715)
- Rigorous double-adjusted analyses (overlap weighting and propensity weighting) for ECMO effect
Limitations
- Observational design cannot fully exclude residual confounding for ECMO selection
- Practice heterogeneity across countries and centers may affect generalizability
Future Directions: Develop validated prognostic tools specific to oncology-ARDS, evaluate patient-centered outcomes, and define contextualized ECMO criteria or alternative strategies tailored to cancer-related ARDS.
PURPOSE: Acute respiratory failure is the leading reason for intensive care unit (ICU) admission among critically ill patients with cancer. We aimed to describe the clinical characteristics, risk factors, and outcomes of patients with cancer and acute respiratory distress syndrome (ARDS) and to evaluate associations of venovenous extracorporeal membrane oxygenation (ECMO) with outcomes in the subgroup with severe ARDS. METHODS: We conducted a multinational, prospective, observational cohort study of patients with cancer and ARDS in 13 countries in Europe and North America. The primary endpoint was 90-day mortality. RESULTS: Among 715 included patients, 73.4% had hematologic malignancies and 26.6% solid tumors; 31.2% had undergone hematopoietic stem-cell transplantation (168 allogeneic). ICU, hospital, and 90-day mortality rates were 55.3%, 70.9%, and 73.2%, respectively. By multivariate analysis, independent predictors of higher 90-day mortality were older age, peripheral vascular disease, severe ARDS at inclusion, acute kidney injury, and ICU admission as a time-limited trial (vs. full code). Conversely, lymphoma was associated with lower 90-day mortality. Among the 322 patients (45.7%) with severe ARDS at inclusion, 90-day mortality was 82.2%; with no difference between patients who received ECMO (n = 58, 18%) and those who did not (82.6% vs. 80.7%, P = 0.89). This finding remained unchanged in a double-adjusted overlap- and propensity-weighted Cox mixed-effects model (adjusted hazard ratio, 1.12; 95% confidence interval 0.65-1.94; P = 0.69). CONCLUSION: Patients with cancer and ARDS, particularly severe forms, experience high 90-day mortality, irrespective of ECMO use. These findings suggest a need for nuanced ICU goals-of-care discussions and raise concerns about the generalizability of ECMO guidelines to this population.
3. Association Between Anticoagulant Therapy and Survival in Pulmonary Arterial Hypertension: A Registry Report and Updated Meta-Analysis.
In a nationwide propensity-adjusted registry (n=1,597) and an updated meta-analysis, anticoagulant therapy did not improve survival in PAH overall or in key subgroups (idiopathic/heritable/anorexigen-associated PAH; connective tissue disease–associated PAH). Median survival was similar between anticoagulated and non-anticoagulated patients.
Impact: Clarifies a long-debated practice by showing no survival benefit of anticoagulation in PAH across subgroups, supporting de-implementation and focusing on disease-targeted therapies.
Clinical Implications: Routine anticoagulation should not be used solely to improve survival in PAH. Decisions should be individualized for other indications (e.g., atrial fibrillation, VTE) while prioritizing guideline-directed PAH therapies.
Key Findings
- No survival difference with anticoagulation in the French national PAH registry (HR 0.997; p=0.97).
- Updated meta-analysis showed no survival benefit overall (HR 0.98) or in idiopathic/heritable/anorexigen-related PAH and connective tissue disease–associated PAH.
- Median survival was similar between anticoagulated (5.62 years) and non-anticoagulated (5.37 years) patients.
Methodological Strengths
- Nationwide propensity-adjusted registry analysis with subgroup consistency
- Integration with updated meta-analysis across nationwide datasets
Limitations
- Observational design cannot exclude residual confounding and dosing/agent heterogeneity
- Lack of randomized data; bleeding outcomes not detailed in the abstract
Future Directions: Randomized trials or pragmatic registries with granular anticoagulation exposure and bleeding outcomes are needed; explore biomarkers or phenotypes identifying subgroups that might benefit.
BACKGROUND: The role of anticoagulant therapy in the management of pulmonary arterial hypertension (PAH) remains uncertain, as existing epidemiologic studies have produced conflicting results. OBJECTIVES: The goal of this study was to examine the association between anticoagulant therapy and survival in PAH. METHODS: A propensity score-based analysis was conducted using data from the national French Pulmonary Hypertension Registry. The findings were then incorporated into an updated meta-analysis of nationwide data sets. RESULTS: Among the 1,597 patients diagnosed with PAH between 2009 and 2020, a total of 380 received anticoagulants at diagnosis. Median survival was 5.62 years (95% CI: 4.76-6.58) for patients receiving anticoagulants and 5.37 years (95% CI: 4.96-5.82) for those not receiving anticoagulants (HR: 0.997; 95% CI: 0.84-1.18; log-rank test, P = 0.97). Findings were consistent across all PAH subgroups within the registry. The updated meta-analysis yielded similar results, with no statistically significant association between anticoagulant use and survival in the overall PAH population (HR: 0.98; 95% CI: 0.78-1.23), as well as in 2 predefined subgroups: 1) idiopathic/heritable PAH or PAH associated with anorexigens (HR: 0.99; 95% CI: 0.79-1.25); and 2) PAH associated with connective tissue disease (HR: 0.86; 95% CI: 0.52-1.42). CONCLUSIONS: Anticoagulant use in PAH was not associated with overall survival in the nationwide registry. These results were supported by an updated meta-analysis. Randomized controlled trials remain the most reliable approach to definitively assess the therapeutic value of anticoagulation in this population.